Reaching New ASCENTs: A Journal Club on sacituzumab govitecan Plus pembrolizumab in Advanced Triple-Negative Breast Cancer
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
As the treatment landscape in advanced triple-negative breast cancer continues to evolve, new data are shaping decision-making in the metastatic setting. This CE-accredited webinar will explore the ASCENT-04/KEYNOTE-D19 trial and the role of sacituzumab govitecan plus pembrolizumab in PD-L1–positive metastatic triple-negative breast cancer.
NCODA Fellow, Madelyn Floysand, PharmD, will review the current treatment landscape, walk through the trial design and methodology, and highlight the key efficacy and safety findings. Case-based scenarios will also help bring the data into practice.
Learning Objectives:
- Discuss the current treatment landscape of advanced triple-negative breast cancer
- Describe the study design and methodology of the ASCENT-04/KEYNOTE-D19 trial
- Summarize the key efficacy and safety results of the ASCENT-04/KEYNOTE-D19 trial
- Apply ASCENT-04/KEYNOTE-D19 findings to clinical decision-making for PD-L1–positive metastatic triple-negative breast cancer using case-based scenarios
This activity has been approved for CE credit for pharmacists and pharmacy technicians only.
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.